MarketPulse — Real-Time Financial News & Market Analysis

DeepBrain AI launches real-time conversational video agents for enterprises, shifting from static video generation. Already deployed at SAP, Shinhan Bank, and Samsung Securities.

Alibaba unveils XuanTie C950 chip with 3x performance gains, advancing custom AI semiconductor strategy. T-Head division has shipped 470,000 chips generating $1.45B annual revenue.

S&P 500 rebounds 1.15% after touching August lows. Ten stocks down 15-37% now show 22-80% upside potential despite geopolitical uncertainty.

Analysts forecast tech and consumer discretionary sectors will outperform S&P 500 by 39% and 30%. Two Vanguard ETFs offer exposure, though concentration risk warrants caution.

Wall Street analysts project AST SpaceMobile and Intuitive Machines could decline 56% and 50% respectively through 2026, citing valuation concerns, competitive pressures, and execution risks.

Trump proposes shared Strait of Hormuz control with Iran, triggering 8% oil price decline to $98.65/barrel amid growing diplomatic momentum.

Paranovus ($PAVS) stock surged 53.6% after terminating dilutive ATM offering, though it's down 100% from $140 52-week high.

Amazon invests $200B in AI infrastructure, faces near-term cash flow challenges, but AWS's 24% growth and long-term potential signal generational opportunity for patient investors.

S&P 500 faces bearish technical pressure toward 6400 amid elevated VIX and global bond stress, though Trump's Iran de-escalation comments provide near-term relief.

Ekinops acquires French ZTNA startup Chimere to strengthen its SASE portfolio and claim position as Europe's sole single-vendor SASE provider.

S&P 500 futures reverse after Iran denies deal talks contradicting Trump's Monday announcement. Oil recovers overnight amid diplomatic uncertainty while manufacturing PMI data looms.

Nvidia stock could gain 74% to $300 by 2030 despite current 7% YTD decline, as CEO projects $1 trillion revenue from next-gen chips.

Roche launches cobas eplex RP3, detecting 25 pathogens simultaneously across CE markets, enabling faster clinical decisions and improved patient outcomes.

Pharming secures Japan approval for Joenja, first APDS treatment for children aged 4-11 globally, based on positive Phase III data showing lymphadenopathy reduction and immune function improvement.

DSM-Firmenich initiated €540M share repurchase program on March 12, 2026. By March 20, company bought back 652,398 shares at €58.81 average price.

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.

Estée Lauder shares fell 7.72% to $79.29 after announcing preliminary merger discussions with Spanish luxury giant Puig Brands. No final decision made; deal pending regulatory approval.

Hormel and General Mills trade at depressed valuations with 5.2% and 6.5% dividend yields amid consumer spending concerns and GLP-1 drug headwinds.

Phonak's AI hearing aids win 2026 excellence awards, featuring advanced environmental recognition and neural networks for improved speech clarity in noisy settings.